The 2026 JAMA Internal Medicine cluster randomized clinical trial by Verma and colleagues provides the strongest evidence to date that structured palliative care for end-stage liver disease (ESLD) can be effectively delivered by hepatologists trained in primary palliative care.
Across 19 US centers and 935 patients with decompensated cirrhosis or hepatocellular carcinoma, quality of life improved significantly in both the hepatologist-led and specialist palliative care arms; hepatologist-delivered care met a prespecified noninferiority criterion.
Secondary outcomes reinforce the signal: symptom burden and depression improved in both groups, while patient satisfaction improved more in the hepatologist arm, suggesting that embedded liver clinicians may offer practical advantages in continuity and acceptability.
These findings align with the broader serious-illness palliative care literature, which shows consistent benefits for symptom control, communication, and patient-centered outcomes, and they help address a major implementation bottleneck in hepatology: limited access to specialty palliative care.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.